Extended Data Fig. 4. Chemokine antibodies in COVID-19 convalescents over time and upon COVID-19 vaccination.
(a) Diagram of the time points of blood collection after onset of COVID-19 symptoms in the Lugano cohort. (b) AUC of ELISA showing RBD IgG antibodies at month 6 and 12 in vaccinated (n = 19) and non-vaccinated (n = 40) COVID-19 convalescents from the Lugano cohort. Average from two independent experiments. Two-tailed Wilcoxon signed-rank test. (c) AUC of ELISA showing chemokine antibodies in COVID-19 convalescents from the Lugano cohort at month 6 and 12 (n = 63). Two independent experiments. Two-tailed Wilcoxon signed-rank test. (d) Diagram of the time points of blood collection after onset of COVID-19 symptoms in a subset of previously hospitalized COVID-19 convalescents from the Lugano cohort. (e) ELISA showing CCL19, CCL22 and CXCL17 antibodies in healthy controls (Control, n = 10) and COVID-19 convalescents (COVID-19) from the Lugano cohort at day 15 (acute, n = 12), and at month 6 (n = 12), 12 (n = 11) and 18 (n = 7). Average OD450 values from two independent experiments. One-way ANOVA test followed by Tukey’s multiple comparison test. Data are shown as median±range. (f) AUC of ELISA showing chemokine antibodies in SARS-CoV-2 naïve individuals (n = 16) before and at month 4 on average after COVID-19 mRNA vaccination. Two independent experiments. Pink lines represent the signal of a positive control plasma sample with broad reactivity (CLM70). RBD IgG is shown alongside as control (right panel). Two-tailed Wilcoxon signed-rank test with false discovery rate (FDR) approach.